NMR spectroscopic characterization of metoprolol/cyclodextrin complexes in aqueous solution: Cavity size dependency

Study of the Structural Chemistry of the Inclusion Complexation of 4-Phenylbutyrate and Related Compounds with Cyclodextrins in Solution: Differences in Inclusion Mode with Cavity Size Dependency

4-phenylbutyrate (PB) and structurally related compounds hold promise for treating many diseases, including cancers. However, pharmaceutical limitations, such as an unpleasant taste or poor aqueous solubility, impede their evaluation and clinical use. This study explores cyclodextrin (CD) complexation as a strategy to address these limitations. The structural chemistry of the CD complexes of these compounds was analyzed using phase solubility, nuclear magnetic resonance (NMR) spectroscopic techniques, and molecular modeling to inform the choice of CD for such application. The study revealed that PB and its shorter-chain derivative form 1:1 αCD complexes, while the longer-chain derivatives form 1:2 (guest:host) complexes. αCD includes the alkyl chain of the shorter-chain compounds, depositing the phenyl ring around its secondary rim, whereas two αCD molecules sandwich the phenyl ring in a secondary-to-secondary rim orientation for the longer-chain derivatives. βCD includes each compound to form 1:1 complexes, with their alkyl chains bent to varying degrees within the CD cavity. γCD includes two molecules of each compound to form 2:1 complexes, with both parallel and antiparallel orientations plausible. The study found that αCD is more suitable for overcoming the pharmaceutical drawbacks of PB and its shorter-chain derivative, while βCD is better for the longer-chain derivatives.

NMR, CD and UV spectroscopic studies reveal uncommon binding modes of dapoxetine to native cyclodextrins

Complex formation between the selective serotonin reuptake inhibitor drug (S)-dapoxetine (Dpx) and β-, γ-, and methylated γ-cyclodextrins (CyDs) was studied by complementary experimental techniques.

Complexation of [2.2]paracyclophane with β- and γ-cyclodextrins studied by HPLC and NMR

The NMR spectra of [2.2]paracyclophane with β- or γ-cyclodextrin in DMF-d7 at room temperature do not show significant complexation, while HPLC of the complexes in mixed H2O:alcohol solvents demonstrate complexation with different stoichiometries. At 243 K in DMF solution the H3 and H5 NMR signals of γ-cyclodextrin (but not β) exhibit complexation-induced chemical shifts denoting complex formation. According to HPLC, at room temperature the [2.2]paracyclophane complex with β-cyclodextrin in 20% H2O:EtOH exhibits 1:2 stoichiometry with K 1 = 1×102 ± 2, K 2 = 9.0×104 ± 2×103 (K = 9×106) while that with γ-cyclodextrin in 50% H2O:MeOH exhibits 1:1 stoichiometry with K 1 = 4×103 ± 150 M−1. Thermodynamic parameters for both complexes have been estimated from the retention time temperature dependence. For the β-cyclodextrin complexation at 25°C ΔG 0CD is −39.7 kJ mol−1 while ΔH 0CD and ΔS 0CD are −88.2 kJ mol−1 and −0.16 kJ mol−1 K−1. For γ-cyclodextrin, the corresponding values are ΔG 0CD = −20.5 kJ mol−1, ΔH 0CD = −33.5 kJ mol−1 and ΔS 0CD = −0.04 kJ mol−1 K−1.

A bilogarithmic method for the spectrophotometric evaluation of stability constants of 1:1 weak complexes from mole ratio data

The absorbance changes that occur when the mole ratio of the components of ligand complex equilibria is varied while the concentration of one component is kept constant (mole ratio method) allow evaluating stability constants in favourable conditions. Values of the corresponding stability (association) constants are normally assigned on the basis of spectrophotometric analysis. Determination of stability constants can be performed by a number of linear procedures, but most of these, suffer from theoretical and practical drawbacks, e.g., linear transformation of the rectangular hyperbola type of binding constants, is valid only when one of the two species is present in a large excess. A rigorous treatment of the experimental mole ratio data for 1:1 weak complexes is carried out in this paper with the aim of eliminating some of the assumptions involved in the other methods usually applied for evaluating stability constants. Orthogonal regression is required in order to take into account the error in both axes. The method has been applied to literature data for the iron(III)-thiocyanate and nickel(II)-selenocyanate systems, as well as to a number of host-guest cyclodextrin complexes.

Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: Formation of aggregates and higher-order complexes

It is well known that water-soluble cyclodextrins form inclusion complexes with many lipophilic water-insoluble drugs and that such complexation frequently enhances the aqueous solubility of drugs. It is also well known that various excipients, such as water-soluble polymers, organic acids and bases and metal ions can enhance the solubilizing effects of cyclodextrins. However, it is not clear how these excipients enhance the effects. The effects of cyclodextrins, 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) and randomly methylated beta-cyclodextrin (RMbetaCD) on the aqueous solubility of triclosan and triclocarban were investigated. The phase-solubility profiles were all of type A(P) indicating formation of higher-order complexes or complex aggregates. Addition of lysine and other excipients enhanced the RMbetaCD solubilization of triclocarban. NMR spectroscopic studies, including 2D ROESY and 1D gROESY techniques, indicated that HPbetaCD and RMbetaCD, as well as their complexes, form aggregates of two to three cyclodextrin molecules. The critical concentration for the aggregate formation was determined to be 5.4% (w/v). Lysine, polyvinylpyrrolidone and magnesium ions formed non-inclusion complexes resulting in formation of multiple-component cyclodextrin complexes in aqueous solutions with triclocarban.

Continuous variation data: 1:1 or 2:2 weak complexes?

An attempt to distinguish between 1:1 and 2: 2 weak complexes from continuous variation data is given. A modification of the Heller and Schwarzenbach's method which involves the use of the absorbance ratio y=A/A(lim) (once the limiting absorbance, A(lim) is known) may be applied to 1:1 weak complexes. This allows checking if the slope obtained is close to the theoretical value of -0.25. A curvature appears and the residuals have a pattern when a wrong 1:1 model is selected for a true 2:2 stoichiometry.

Design and evaluation of cyclodextrin-based drug formulation

The pharmaceutically useful cyclodextrins (CyDs) are classified into hydrophilic, hydrophobic, and ionic derivatives. Because of the multi-functional characteristics and bioadaptability, these CyDs are capable of alleviating the undesirable properties of drug molecules through the formation of inclusion complexes or the form of CyD/drug conjugates. This review outlines the current application of CyDs in design and evaluation of CyD-based drug formulation, focusing on their ability to enhance the drug absorption across biological barriers, the ability to control the rate and time profiles of drug release, and the ability to deliver a drug to a targeted site.

[Pharmaceutical application of cyclodextrins as multi-functional drug carriers]

Owing to the increasingly globalized nature of the cyclodextrin (CyD)-related science and technology, development of the CyD-based pharmaceutical formulation is rapidly progressing. The pharmaceutically useful CyDs are classified into hydrophilic, hydrophobic, and ionic derivatives. Because of the multi-functional characteristics and bioadaptability, these CyDs are capable of alleviating the undesirable properties of drug molecules through the formation of inclusion complexes or the form of CyD/drug conjugates. This review outlines the current application of CyDs in drug delivery and pharmaceutical formulation, focusing on the following evidences. 1) The hydrophilic CyDs enhance the rate and extent of bioavailability of poorly water-soluble drugs. 2) The amorphous CyDs such as 2-hydroxypropyl-beta-CyD are useful for inhibition of polymorphic transition and crystallization rates of drugs during storage. 3) The delayed release formulation can be obtained by the use of enteric type CyDs such as O-carboxymethyl-O-ethyl-beta-CyD. 4) The hydrophobic CyDs are useful for modification of the release site and/or time profile of water-soluble drugs with prolonged therapeutic effects. 5) The branched CyDs are particularly effective in inhibiting the adsorption to hydrophobic surface of containers and aggregation of polypeptide and protein drugs. 6) The combined use of different CyDs and/or pharmaceutical additives can serve as more functional drug carriers, improving efficacy and reducing side effects. 7) The CyD/drug conjugates may provide a versatile means for the constructions of not only colonic delivery system but also site-specific drug release system, including gene delivery. On the basis of the above-mentioned knowledge, the advantages and limitations of CyDs in the design of advanced dosage forms will be discussed.